• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Btbd7 contributes to reduced E-cadherin expression and predicts poor prognosis in non-small cell lung cancer
Conclusions: Btbd7 contributes to reduced expression of E-cadherin and may be a promising cancer marker in non-small cell lung cancer.
Source: BMC Cancer - September 24, 2014 Category: Cancer & Oncology Authors: Chuifeng FanYuan MiaoXiupeng ZhangDi LiuGuiyang JiangXuyong LinQiang HanLan LuanZhonghai XuEnhua Wang Source Type: research

Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival
Conclusion: We have shown that combined ↑cancer and ↑stromal cell CXCL16 expression is an independent positive prognostic factor in NSCLC. Further studies are warranted to elucidate the biological mechanism underlying this finding.
Source: BMC Cancer - May 29, 2015 Category: Cancer & Oncology Authors: Sigurd HaldYury KiselevSamer Al-SaadElin RichardsenCharles JohannessenMarte EilertsenThomas KilvaerKhalid Al-ShibliSigve AndersenLill-Tove BusundRoy BremnesTom Donnem Source Type: research

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines
Conclusions: We identified DKK1 as a possible marker of a cisplatin-refractory phenotype and as a potential novel therapeutic target to improve platinum response of NSCLC cells.
Source: BMC Cancer - September 9, 2015 Category: Cancer & Oncology Authors: Hogir SalimDali ZongPetra HåågMetka NovakBirgitta MörkRolf LewensohnLovisa LundholmKristina Viktorsson Source Type: research

Abnormal expression of Pygopus 2 correlates with a malignant phenotype in human lung cancer
Conclusions: We therefore conclude that abnormal Pygo2 protein expression may be a marker for advanced NSCLC. Furthermore, Pygo2 knockdown suppresses cell growth.
Source: BMC Cancer - July 16, 2013 Category: Cancer & Oncology Authors: Yang LiuQian-Ze DongSi WangChang-Qing FangYuan MiaoLiang WangMing-Zhu LiEn-Hua Wang Source Type: research

Evaluation of a curcumin analog as an anti-cancer agent inducing ER stress-mediated apoptosis in non-small cell lung cancer cells
Conclusions: A new monocarbonyl analog of curcumin, B82, exhibited anti-tumor effects on H460 cells via an ER stress-mediated mechanism. B82 could be further explored as a potential anticancer agent for the treatment of NSCLC.
Source: BMC Cancer - October 24, 2013 Category: Cancer & Oncology Authors: Zhiguo LiuYusheng SunLuqing RenYi HuangYuepiao CaiQiaoyou WengXueqian ShenXiaokun LiGuang LiangYi Wang Source Type: research

The novel IGF-IR/Akt¿dependent anticancer activities of glucosamine
Conclusions: Taken together, our results suggest that targeting the IGF-1R/Akt pathway with glucosamine may be an effective therapeutic strategy for treating some type of cancer.
Source: BMC Cancer - January 20, 2014 Category: Cancer & Oncology Authors: Ki-Hoon SongJu-Hee KangJong-Kyu WooJeong-Seok NamHye-Young MinHo-Young LeeSoo-Youl KimSeung-Hyun Oh Source Type: research

Role of Pax8 in the regulation of MET and RON receptor Tyrosine Kinases in non-small cell lung cancer
Conclusion: PAX8 provides signals for growth and motility of NSCLC cells and is necessary for MET and RON expression. Further investigations are necessary to investigate the therapeutic potential of PA8 in NSCLC.
Source: BMC Cancer - March 14, 2014 Category: Cancer & Oncology Authors: Rajani KantetiEssam El-HashaniImmanuel DhanasinghMaria TretiakovaAliya HusainSherven SharmaJay SharmaEverett VokesRavi Salgia Source Type: research

microRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18
Conclusions: We demonstrated that miR-30b/c was down-regulated in NSCLC specimens compared with adjacent non-tumor tissues. miR-30b/c directly targeted and down-regulated Rab18 expression and inhibited NSCLC cells proliferation. These data indicated that miR-30b/c could serve as a tumor suppressor gene involved in NSCLC pathogenesis.
Source: BMC Cancer - September 24, 2014 Category: Cancer & Oncology Authors: Keng ZhongKun ChenLin HanBailing Li Source Type: research

Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma
Conclusions: Together, these data highlight a broader role for dysregulated MAPK7 in driving tumorigenesis within niche populations of highly prevalent tumor types, and describe current efforts in establishing a robust drug discovery screening cascade.
Source: BMC Cancer - June 4, 2015 Category: Cancer & Oncology Authors: Paul GavineMei WangDehua YuEva HuChunlei HuangJenny XiaXinying SuJoan FanTianwei ZhangQingqing YeLi ZhengGuanshan ZhuZiliang QianQingquan LuoYing HouQunsheng Ji Source Type: research

P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement
Conclusion: P-gp over-expression is a possible mechanism of acquired resistance to 17-DMAG in cells with ALK rearrangement.
Source: BMC Cancer - July 29, 2015 Category: Cancer & Oncology Authors: Hee KimKye LeeYoung KimYun ChoiJung-Eun LeeChang ChoiIn-Jeoung BaekJin RhoJae Lee Source Type: research